drugset
drugset / Trial / NCT06003088

Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers

NCT06003088 ↗

Phase 1 Completed 48 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the relative bioavailability of HSK7653(5mg) given as formulation A versus formulation B. To investigate the relative bioavailability of HSK7653(25mg) given as formulation A versus formulation B. To investigate safety and pharmacodynamics of two doses of HSK7653 in healthy male subjects.

Timeline

Start
2022-06-15
Primary completion
2022-08-12
Completion
2022-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK7653 Unknown 5 mg Oral
Subject HSK7653 Unknown 25 mg Oral

Indications

No indication recorded.